vs
agilon health, inc.（AGL）与Sotera Health Co（SHC）财务数据对比。点击上方公司名可切换其他公司
agilon health, inc.的季度营收约是Sotera Health Co的5.2倍（$1.6B vs $303.4M）。Sotera Health Co净利率更高（11.5% vs -12.0%，领先23.5%）。Sotera Health Co同比增速更快（4.6% vs 3.1%）。Sotera Health Co自由现金流更多（$52.4M vs $-23.5M）。过去两年Sotera Health Co的营收复合增速更高（10.6% vs -1.1%）
agilon health是一家美国医疗保健企业，主要与基层医疗服务提供者合作，为联邦医疗保险覆盖的老年群体提供价值导向型医疗解决方案，为医生提供行政支持、临床工具及风险管理框架，在提升诊疗效果的同时降低医疗成本，业务覆盖美国20余个州。
Sotera Health Co是全球领先的医疗安全解决方案提供商，面向医疗器械厂商、制药企业、食品及消费品公司提供灭菌服务、实验室分析检测与合规咨询支持，帮助客户满足监管要求，保障上市产品的使用安全。
AGL vs SHC — 直观对比
营收规模更大
AGL
是对方的5.2倍
$303.4M
营收增速更快
SHC
高出1.5%
3.1%
净利率更高
SHC
高出23.5%
-12.0%
自由现金流更多
SHC
多$75.9M
$-23.5M
两年增速更快
SHC
近两年复合增速
-1.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $303.4M |
| 净利润 | $-188.9M | $34.8M |
| 毛利率 | — | 54.7% |
| 营业利润率 | -12.3% | 23.2% |
| 净利率 | -12.0% | 11.5% |
| 营收同比 | 3.1% | 4.6% |
| 净利润同比 | -78.5% | 182.8% |
| 每股收益（稀释后） | — | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGLSHC
| Q4 25 | $1.6B | $303.4M | ||
| Q3 25 | $1.4B | $311.3M | ||
| Q2 25 | $1.4B | $294.3M | ||
| Q1 25 | $1.5B | $254.5M | ||
| Q4 24 | $1.5B | $290.2M | ||
| Q3 24 | $1.5B | $285.5M | ||
| Q2 24 | $1.5B | $276.6M | ||
| Q1 24 | $1.6B | $248.2M |
净利润AGLSHC
| Q4 25 | $-188.9M | $34.8M | ||
| Q3 25 | $-110.2M | $48.4M | ||
| Q2 25 | $-104.4M | $8.0M | ||
| Q1 25 | $12.1M | $-13.3M | ||
| Q4 24 | $-105.8M | $12.3M | ||
| Q3 24 | $-117.6M | $17.0M | ||
| Q2 24 | $-30.7M | $8.8M | ||
| Q1 24 | $-6.1M | $6.3M |
毛利率AGLSHC
| Q4 25 | — | 54.7% | ||
| Q3 25 | — | 57.0% | ||
| Q2 25 | — | 56.6% | ||
| Q1 25 | — | 53.2% | ||
| Q4 24 | — | 56.6% | ||
| Q3 24 | — | 55.4% | ||
| Q2 24 | — | 55.2% | ||
| Q1 24 | — | 51.2% |
营业利润率AGLSHC
| Q4 25 | -12.3% | 23.2% | ||
| Q3 25 | -9.1% | 23.4% | ||
| Q2 25 | -8.3% | 6.4% | ||
| Q1 25 | -1.4% | -5.8% | ||
| Q4 24 | -7.1% | 30.0% | ||
| Q3 24 | -9.2% | 28.2% | ||
| Q2 24 | -2.9% | 27.8% | ||
| Q1 24 | -0.4% | 21.4% |
净利率AGLSHC
| Q4 25 | -12.0% | 11.5% | ||
| Q3 25 | -7.7% | 15.5% | ||
| Q2 25 | -7.5% | 2.7% | ||
| Q1 25 | 0.8% | -5.2% | ||
| Q4 24 | -6.9% | 4.2% | ||
| Q3 24 | -8.1% | 6.0% | ||
| Q2 24 | -2.1% | 3.2% | ||
| Q1 24 | -0.4% | 2.5% |
每股收益（稀释后）AGLSHC
| Q4 25 | — | $0.12 | ||
| Q3 25 | — | $0.17 | ||
| Q2 25 | — | $0.03 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | — | $0.06 | ||
| Q2 24 | — | $0.03 | ||
| Q1 24 | — | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $173.7M | $344.6M |
| 总债务越低越好 | $35.0M | $2.1B |
| 股东权益账面价值 | $126.7M | $606.0M |
| 总资产 | $1.3B | $3.3B |
| 负债/权益比越低杠杆越低 | 0.28× | 3.53× |
8季度趋势，按日历期对齐
现金及短期投资AGLSHC
| Q4 25 | $173.7M | $344.6M | ||
| Q3 25 | $171.7M | $299.2M | ||
| Q2 25 | $171.4M | $332.4M | ||
| Q1 25 | $136.9M | $304.4M | ||
| Q4 24 | $188.2M | $277.2M | ||
| Q3 24 | $148.2M | $306.7M | ||
| Q2 24 | $109.5M | $246.1M | ||
| Q1 24 | $111.7M | $261.1M |
总债务AGLSHC
| Q4 25 | $35.0M | $2.1B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
股东权益AGLSHC
| Q4 25 | $126.7M | $606.0M | ||
| Q3 25 | $306.1M | $550.5M | ||
| Q2 25 | $408.9M | $511.3M | ||
| Q1 25 | $500.3M | $414.1M | ||
| Q4 24 | $471.0M | $404.9M | ||
| Q3 24 | $574.9M | $470.2M | ||
| Q2 24 | $676.6M | $422.8M | ||
| Q1 24 | $689.3M | $429.4M |
总资产AGLSHC
| Q4 25 | $1.3B | $3.3B | ||
| Q3 25 | $1.6B | $3.2B | ||
| Q2 25 | $1.7B | $3.2B | ||
| Q1 25 | $1.9B | $3.1B | ||
| Q4 24 | $1.7B | $3.1B | ||
| Q3 24 | $2.1B | $3.1B | ||
| Q2 24 | $2.2B | $3.1B | ||
| Q1 24 | $2.3B | $3.1B |
负债/权益比AGLSHC
| Q4 25 | 0.28× | 3.53× | ||
| Q3 25 | — | 3.89× | ||
| Q2 25 | — | 4.34× | ||
| Q1 25 | — | 5.36× | ||
| Q4 24 | — | 5.49× | ||
| Q3 24 | — | 4.73× | ||
| Q2 24 | — | 5.26× | ||
| Q1 24 | — | 5.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-20.5M | $103.1M |
| 自由现金流经营现金流 - 资本支出 | $-23.5M | $52.4M |
| 自由现金流率自由现金流/营收 | -1.5% | 17.3% |
| 资本支出强度资本支出/营收 | 0.2% | 16.7% |
| 现金转化率经营现金流/净利润 | — | 2.96× |
| 过去12个月自由现金流最近4个季度 | $-119.0M | $149.2M |
8季度趋势，按日历期对齐
经营现金流AGLSHC
| Q4 25 | $-20.5M | $103.1M | ||
| Q3 25 | $-18.2M | $71.2M | ||
| Q2 25 | $-35.1M | $57.4M | ||
| Q1 25 | $-32.0M | $55.5M | ||
| Q4 24 | $16.4M | $55.7M | ||
| Q3 24 | $-7.7M | $97.5M | ||
| Q2 24 | $-18.7M | $61.3M | ||
| Q1 24 | $-47.8M | $9.7M |
自由现金流AGLSHC
| Q4 25 | $-23.5M | $52.4M | ||
| Q3 25 | $-21.3M | $35.0M | ||
| Q2 25 | $-38.3M | $26.2M | ||
| Q1 25 | $-35.8M | $35.6M | ||
| Q4 24 | $13.2M | $-10.2M | ||
| Q3 24 | $-11.2M | $61.1M | ||
| Q2 24 | $-22.0M | $19.4M | ||
| Q1 24 | $-50.9M | $-25.2M |
自由现金流率AGLSHC
| Q4 25 | -1.5% | 17.3% | ||
| Q3 25 | -1.5% | 11.2% | ||
| Q2 25 | -2.7% | 8.9% | ||
| Q1 25 | -2.3% | 14.0% | ||
| Q4 24 | 0.9% | -3.5% | ||
| Q3 24 | -0.8% | 21.4% | ||
| Q2 24 | -1.5% | 7.0% | ||
| Q1 24 | -3.2% | -10.2% |
资本支出强度AGLSHC
| Q4 25 | 0.2% | 16.7% | ||
| Q3 25 | 0.2% | 11.6% | ||
| Q2 25 | 0.2% | 10.6% | ||
| Q1 25 | 0.3% | 7.8% | ||
| Q4 24 | 0.2% | 22.7% | ||
| Q3 24 | 0.2% | 12.7% | ||
| Q2 24 | 0.2% | 15.2% | ||
| Q1 24 | 0.2% | 14.1% |
现金转化率AGLSHC
| Q4 25 | — | 2.96× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | 7.21× | ||
| Q1 25 | -2.64× | — | ||
| Q4 24 | — | 4.52× | ||
| Q3 24 | — | 5.73× | ||
| Q2 24 | — | 7.00× | ||
| Q1 24 | — | 1.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AGL
| Medical Services | $1.6B | 100% |
| Other Operating | $2.5M | 0% |
SHC
| Transferred At Point In Time | $198.4M | 65% |
| Nelson Labs | $55.2M | 18% |
| Nordion | $49.8M | 16% |
